Dual Thrombolytic Therapy With Mutant Prourokinase and Small Bolus Alteplase for Ischemic Stroke
This randomized clinical trial of individuals with ischemic stroke assesses the safety and efficacy of treatment with a dual plasminogen activator vs usual treatment with intravenous alteplase. (Source: JAMA Neurology)
Source: JAMA Neurology - May 22, 2023 Category: Neurology Source Type: research
Segmental Uniparental Isodisomy and “Inside-to-Outside” Limb-Girdle Muscular Dystrophy
This case report describes segmental uniparental isodisomy causing an “inside-to-outside” limb-girdle muscular dystrophy due to a homozygous mutation in POGLUT1. (Source: JAMA Neurology)
Source: JAMA Neurology - May 22, 2023 Category: Neurology Source Type: research
AHSCT vs Fingolimod, Natalizumab, and Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
This comparative effectiveness research study compares autologous hematopoietic stem cell transplant (AHSCT) vs fingolimod, natalizumab, and ocrelizumab for patients with relapsing-remitting multiple sclerosis. (Source: JAMA Neurology)
Source: JAMA Neurology - May 15, 2023 Category: Neurology Source Type: research
Risk of Parkinson Disease Among Camp Lejeune Veterans
This cohort study assesses the association between the contaminated water supply at Camp Lejeune and incidence of Parkinson disease among veterans who resided there between 1975 and 1985. (Source: JAMA Neurology)
Source: JAMA Neurology - May 15, 2023 Category: Neurology Source Type: research
Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States
This cohort study analyzes data from representative private, military, and public health insurance data sets to calculate the national prevalence of multiple sclerosis among Hispanic, non-Hispanic Black, and non-Hispanic White individuals in the United States. (Source: JAMA Neurology)
Source: JAMA Neurology - May 15, 2023 Category: Neurology Source Type: research
Camp Lejeune, Trichloroethylene, and Parkinson Disease
The benefit of the doubt should go to the people, not the chemical.Retired Master Sergeant Jerry Ensminger (Source: JAMA Neurology)
Source: JAMA Neurology - May 15, 2023 Category: Neurology Source Type: research
Making Sure Multiple Sclerosis Counts and Is Counted for All
Physicians have long been taught that multiple sclerosis (MS) is a disease predominantly affecting people of European ancestry, especially those who identify as White. There are many factors that have contributed to this error, including the fact that early epidemiologic studies in MS focused heavily on areas with significant White populations, and data regarding racial or ethnic identity were not routinely collected or evaluated. In the 1970s, MS was called the “white man’s burden spread from western Europe.” These teachings likely compounded underascertainment of MS and compounded existing limitations in access to ...
Source: JAMA Neurology - May 15, 2023 Category: Neurology Source Type: research
Autologous Stem Cell Transplant vs Disease-Modifying Therapy for Multiple Sclerosis
The availability of an increasingly wide array of disease-modifying therapies (DMTs) for multiple sclerosis (MS), including the currently more than 20 US Food and Drug Administration –approved therapies, illustrates remarkable progress in treatment of the disease. These available treatments achieve their efficacy via a variety of different mechanisms of action but also exhibit varying degrees of overall effectiveness, safety, and tolerability. Despite treatment with these ther apies, there are some people with highly active MS who experience continued relapses, new magnetic resonance imaging (MRI) lesions, or disability ...
Source: JAMA Neurology - May 15, 2023 Category: Neurology Source Type: research
A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials
This Viewpoint calls for comprehensive investigations into sex differences associated with treatments in existing Alzheimer disease and integration into future Alzheimer disease and related dementia clinical trials. (Source: JAMA Neurology)
Source: JAMA Neurology - May 8, 2023 Category: Neurology Source Type: research
Brain Regions for Measuring Change in Longitudinal Tau PET in Alzheimer Disease
This cohort study investigates if defining participant-level regions of interest improves sensitivity to tau accumulation on positron emission tomography compared with group-level regions of interest. (Source: JAMA Neurology)
Source: JAMA Neurology - May 8, 2023 Category: Neurology Source Type: research
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients
This randomized clinical trial compares data for the timing of amyloid positron emission tomography for patients with concerns about cognitive decline to determine its clinical effect early in the diagnostic workup (within 1 month). (Source: JAMA Neurology)
Source: JAMA Neurology - May 8, 2023 Category: Neurology Source Type: research
CT Findings in Hyperacute Spontaneous Midbrain Hemorrhage
This case report describes the computed tomography (CT) characteristic findings and evolution of a hyperacute spontaneous midbrain hemorrhage. (Source: JAMA Neurology)
Source: JAMA Neurology - May 8, 2023 Category: Neurology Source Type: research
JAMA Neurology
Mission Statement: The mission of JAMA Neurology is to publish and disseminate scientific information primarily important for physicians caring for people with neurologic disorders and for those interested in the structure and function of the normal and diseased human nervous system. The specific aims are to (1) publish timely original research, including clinical trials that will directly improve clinical neurologic care and that will inform efforts to improve neurological health and promote health care equity; (2) report translational research that is pertinent to the understanding of neurologic disease; (3) address topi...
Source: JAMA Neurology - May 1, 2023 Category: Neurology Source Type: research
The Cynicism of the Seronegative
A physician in his 70s describes his path to a diagnosis of inflammatory arthritis, which included completely normal laboratory results. (Source: JAMA Neurology)
Source: JAMA Neurology - May 1, 2023 Category: Neurology Source Type: research
Rheumatoid Arthritis and Risk of Parkinson Disease in Korea
This cohort study evaluates the associations of rheumatoid arthritis and its seropositivity with subsequent Parkinson disease risk in a nationally representative Korean population. (Source: JAMA Neurology)
Source: JAMA Neurology - May 1, 2023 Category: Neurology Source Type: research
